Stock Yards Bank & Trust Co. Cuts Stake in Humana Inc. (NYSE:HUM)

Stock Yards Bank & Trust Co. lowered its holdings in shares of Humana Inc. (NYSE:HUM) by 20.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,067 shares of the insurance provider’s stock after selling 2,295 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Humana were worth $2,300,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV grew its position in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Atwood & Palmer Inc. purchased a new stake in shares of Humana during the third quarter worth about $29,000. Ashton Thomas Securities LLC purchased a new position in Humana during the 3rd quarter valued at approximately $31,000. Your Advocates Ltd. LLP grew its holdings in Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares in the last quarter. Finally, LRI Investments LLC grew its holdings in Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after buying an additional 143 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.29% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on HUM shares. KeyCorp started coverage on Humana in a report on Friday, October 11th. They set a “sector weight” rating for the company. Piper Sandler raised their price target on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Truist Financial raised their price target on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. TD Cowen raised their price objective on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $250.00 price objective on shares of Humana in a research note on Wednesday, October 9th. Nineteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $297.68.

Humana Trading Down 1.2 %

Shares of NYSE:HUM opened at $293.40 on Monday. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The business’s fifty day simple moving average is $275.36 and its 200-day simple moving average is $301.75. The company has a market capitalization of $35.33 billion, a PE ratio of 25.99, a P/E/G ratio of 2.21 and a beta of 0.56. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.